578 related articles for article (PubMed ID: 25046660)
1. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
[TBL] [Abstract][Full Text] [Related]
2. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
4. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
5. Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.
Lorenzi S; Mattei F; Sistigu A; Bracci L; Spadaro F; Sanchez M; Spada M; Belardelli F; Gabriele L; Schiavoni G
J Immunol; 2011 May; 186(9):5142-50. PubMed ID: 21441457
[TBL] [Abstract][Full Text] [Related]
6. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.
Lee SC; Srivastava RM; López-Albaitero A; Ferrone S; Ferris RL
Immunol Res; 2011 Aug; 50(2-3):248-54. PubMed ID: 21717064
[TBL] [Abstract][Full Text] [Related]
7. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
8. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
[TBL] [Abstract][Full Text] [Related]
9. Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells.
Manches O; Lui G; Molens JP; Sotto JJ; Chaperot L; Plumas J
Cytotherapy; 2008; 10(6):642-9. PubMed ID: 18836919
[TBL] [Abstract][Full Text] [Related]
10. Clinically applicable CD34
van Eck van der Sluijs J; van Ens D; Thordardottir S; Vodegel D; Hermens I; van der Waart AB; Falkenburg JHF; Kester MGD; de Rink I; Heemskerk MHM; Borst J; Schaap NPM; Jansen JH; Xiao Y; Dolstra H; Hobo W
Cancer Immunol Immunother; 2021 Nov; 70(11):3167-3181. PubMed ID: 33796917
[TBL] [Abstract][Full Text] [Related]
11. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.
Iyori M; Zhang T; Pantel H; Gagne BA; Sentman CL
J Immunol; 2011 Sep; 187(6):3087-95. PubMed ID: 21832159
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway.
Nagasaki E; Takahara A; Koido S; Sagawa Y; Aiba K; Tajiri H; Yagita H; Homma S
J Immunother; 2010 Jun; 33(5):467-74. PubMed ID: 20463601
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.
Dao T; Gomez-Nunez M; Antczak C; Kappel B; Jaggi JS; Korontsvit T; Zakhaleva V; Scheinberg DA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8763-72. PubMed ID: 16361564
[TBL] [Abstract][Full Text] [Related]
14. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients.
Fauriat C; Moretta A; Olive D; Costello RT
Blood; 2005 Sep; 106(6):2186-8. PubMed ID: 15928036
[TBL] [Abstract][Full Text] [Related]
15. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
16. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
17. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
[TBL] [Abstract][Full Text] [Related]
18. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
J Exp Med; 2002 Jan; 195(1):125-33. PubMed ID: 11781371
[TBL] [Abstract][Full Text] [Related]
19. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
20. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
